Point72 Hong Kong’s iTeos Therapeutics ITOS Stock Holding History

Point72 Hong Kong’s Portfolio ITOS Stock Details ITOS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-2,095	Closed	-$67K	–	2163
2022 Q1	$67K	Buy	+2,095	New	+$76.1K	﹤0.01%	1265

Other funds holding ITOS

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

MAM

MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Point72 Hong Kong's ITOS Position: Q2 2022 in Review

Point72 Hong Kong sold out of iTeos Therapeutics (ITOS) in Q2 2022, closing a stake of 2,095 shares — an estimated $67K sold.

Point72 Hong Kong first reported a position in ITOS in Q1 2022 and held it in 1 quarter. The position peaked at $67K in Q1 2022. 152 funds tracked by Wall St. Rank hold ITOS as of Q2 2022.

Point72 Hong Kong reported no remaining iTeos Therapeutics position as of Q2 2022 after selling out during the quarter.
Point72 Hong Kong sold 2,095 iTeos Therapeutics shares in Q2 2022, an estimated $67K.
Point72 Hong Kong first reported a position in iTeos Therapeutics in Q1 2022 and held it in 1 quarter.
Point72 Hong Kong's iTeos Therapeutics position peaked at $67K in Q1 2022.
152 funds tracked by Wall St. Rank held iTeos Therapeutics as of Q2 2022.

Based on Point72 Hong Kong's 13F filing for Q2 2022, filed 15 Aug 2022.